Mankind Pharma to sell stake in Mahananda Spa and Resorts for Rs 530 crore

Published On 2025-02-11 09:00 GMT   |   Update On 2025-02-11 09:12 GMT

New Delhi: Drugmaker, Mankind Pharma, has announced the sale of its entire stake in Mahananda Spa and Resorts Private Limited, a Wholly Owned Subsidiary Company to Chalet Hotels Limited for an enterprise value of Rs 530 crore. The proceeds of monetization of non-core assets to be utilized to retire part of its debts.

"Pursuant to Regulation 30 of the Listing Regulations, we wish to inform you that the Board appointed Committee of Independent Directors in its meeting held today i.e. February 10, 2025 approved the sale of entire stake held by the Company in Mahananda Spa and Resorts Private Limited (“Mahananda”), a Wholly Owned Subsidiary Company to Chalet Hotels Limited," the Company stated in a BSE filing.

The Transaction Documents, including the Share Purchase Agreement, etc. will be executed in due course and the transaction will be completed by February 28, 2025.

Mahananda Spa had a turnover of Rs 74.33 crore in FY24, and a networth of Rs 401.35 crore.

Read also: Mankind Pharma transfers OTC business to subsidiary Mankind Consumer Products

Chalet Hotels Limited (“Chalet”) is an Indian Hotel Chain Company founded in 1986 and part of K Raheja Corp Group. Chalet is an owner, developer, asset manager and operator of high-end hotels and a hotel led mixed-use developer across India.

Medical Dialogues team had earlier reported that Mankind Pharma had completed the transaction to acquire Bharat Serums and Vaccines Ltd (BSV), for a consideration of Rs 13,768 crore.

Read also: Mankind Pharma Completes Rs 13,768 Crore Acquisition of Bharat Serums

Founded in 1991 and commenced operation in 1995, Mankind Pharma is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

Read also: Mankind Pharma secures Rs 50 billion funding for Bharat Serums acquisition

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News